

<u>Reference</u>	<u>Patient Information</u>
<p>Wagner et al, “Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors,” J. Clin. Oncol. 28:835-840 (2010) at p. 836.</p>	<p>Drug: Rapamycin  Total patients: 3  Tumor type: Perivascular epithelioid cell tumor  Single-arm  Uncontrolled</p>
<p>Piovesan et al., “Response to sirolimus in combination to tyrosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST),” J. Clin. Oncol. 27:10565 (2009) at Abstract.</p>	<p>Drug: Rapamycin plus TKI  Total patients: 3  Tumor type: Gastrointestinal stromal tumors  Single-arm  Uncontrolled</p>
<p>Gonzalez-Angulo et al., “Weekly nab Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial,” Clin. Cancer Res. 19(19):5474-5484 (2013) at pp. 5475, 5477, 5480.</p>	<p>Drug: <i>Nab</i>-rapamycin  Total patients: 27  Treated patients: 26  Patients evaluable: 19  Tumor types (patient number):</p> <ul style="list-style-type: none"> <li>• Bladder (1)</li> <li>• Breast (1)</li> <li>• Colorectal (3)</li> <li>• Esophagus (2)</li> <li>• Head and neck (3)</li> <li>• Kidney (3)</li> <li>• Lung/thoracic (2)</li> <li>• Prostate (1)</li> <li>• Stomach (1)</li> <li>• Uterus (1)</li> <li>• Other (8) <ul style="list-style-type: none"> <li>○ Neuroendocrine (1)</li> </ul> </li> </ul> <p>Single-arm  Uncontrolled  Phase I</p>

<p>Jimeno et al., “Pharmacodynamic Guided Modified Continuous Reassessment Method-Based, Dose Finding Study of Rapamycin in Adult Patients With Solid Tumors,” <i>J. Clin. Oncol.</i> 26:4172-4179 (2008) at pp. 4173, 4175.</p>	<p>Drug: Rapamycin  Total patients: 21  Patients evaluable: 21  Tumor types (patient number):</p> <ul style="list-style-type: none"> <li>• Sarcoma (4)</li> <li>• Pancreas (adenocarcinoma) (4)</li> <li>• Colorectal (3)</li> <li>• Hepatocellular (3)</li> <li>• Neuroendocrine (3)</li> <li>• Other (4)</li> </ul> <p>Single-arm  Uncontrolled  Phase I</p>
<p>Acevedo-Gadea et al., “Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy,” <i>Breast Cancer Res. Treat.</i> 150:157-167 (2015) at pp. 157-159.</p>	<p>Drug: Sirolimus plus trastuzumab  Total patients: 11  Patients evaluable for response: 9  Tumor type: Metastatic HER2-positive breast cancer following disease progression on prior trastuzumab therapy  Single-arm  Uncontrolled  Phase II</p>
<p>Choo et al., “A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma,” <i>Eur. J. Cancer</i> 49:999-1008 (2013) at pp. 999-1000.</p>	<p>Drug: Rapamycin plus bevacizumab  Total patients: 24  Tumor type: Advanced hepatocellular carcinoma  Open-label  Single-arm  Uncontrolled  Phase I</p>
<p>Cloughesy et al., “Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma,” <i>PLoS Medicine</i> 5(1):139-151 (2008) at p. 140.</p>	<p>Drug: Rapamycin  Total patients: 15  Tumor type: glioblastoma  Single-arm  Uncontrolled  Phase I</p>

<p>Marrari et al., “Effect of adding sirolimus (s) to imatinib (im) on tumor response following secondary resistance to im in advanced chordoma,” J. Clin. Oncol. 26:10541 (2008) at Abstract.</p>	<p>Drug: Rapamycin plus imatinib  Total patients: 7  Tumor type: Advanced chordoma  Single-arm  Uncontrolled</p>
<p>Stacchiotti et al., “Sirolimus in advanced hemangioendothelioma,” J Clin. Oncol. 31:10565 (2013) at Abstract.</p>	<p>Drug: Rapamycin  Total patients: 12  Patients evaluable for response: 10  Tumor type: Haemangioendothelioma  Single-arm  Uncontrolled</p>
<p>Stallone et al., “Sirolimus for Kaposi’s Sarcoma in Renal-Transplant Recipients,” NEJM 352:1317-1323 (2005) at p. 1318.</p>	<p>Drug: Rapamycin  Total patients: 15  Tumor type: Kaposi’s sarcoma  Single-arm  Uncontrolled</p>